Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
Animal models tend to leave a lot to be desired when it comes to Alzheimer's research. As a result, there's been considerable activity in developing an "Alzheimer's-in-a-dish" model, and investigators at Lund University in Sweden say they've been making progress on that front.
A new study presented at the Radiological Society of North America highlighted changes in brain connections that could be spotted in an MRI and may offer an imaging biomarker for early Alzheimer's.
Eli Lilly's never-say-die strategy for Alzheimer's has inspired another high-risk campaign in the clinic. The shrinking pharma giant--about to be bumped from the top 10 by a growing Actavis--has launched its pivotal Phase II/III study of its BACE drug for Alzheimer's, newly partnered with AstraZeneca.
Roche never publicly described what went wrong with its early-stage BACE drug for Alzheimer's when it killed the program. But a new study from the pharma giant's Genentech unit outlines the potential threat one of their BACE efforts posed to patients--and how they've managed to adjust for it in animal studies that may well open the door to new human trials.
Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.
Massachusetts General Hospital investigator Rudy Tanzi has created a new "Alzheimer's-in-a-dish" approach to growing brain cells that he claims provides clear proof of the much-debated amyloid hypothesis as well as a solid target for the disease. And now he reportedly plans to race ahead with his new research process to find a potential megablockbuster drug that can stop the disease in its tracks.
German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.
Avanir's combinatorial approach to calming dementia-related outbursts among Alzheimer's patients caught the attention of Wall Street on Monday morning. The biotech touted midstage data demonstrating that a match of two treatments--a generic cough suppressant and a long-approved treatment for irregular heartbeats--significantly reduced the level of agitation among the patients in the study.
Eli Lilly's Alzheimer's imaging agent, Amyvid, can't get very far sales-wise without coverage from the Center for Medicare and Medicaid Services (CMS). And as per a September decision, that's something it doesn't have. Now, however, it's fighting back, funding litigation it couldn't file itself.